**Pharmaceutical Products:** 65%
**Biotechnology:** 20%
**Healthcare Services:** 15%

**TOP 3 Markets:**
**China:** 55%
**USA:** 20%
**Europe:** 15%

North China Pharmaceutical Company Ltd. generates the majority of its revenue from the sale of pharmaceutical products, which account for about two-thirds of total revenue. Another significant portion comes from biotechnology, while healthcare services represent a smaller but growing share.

Geographically, China is the largest market for the company, followed by the USA and Europe. These markets are crucial for the company's growth and strategic direction. The strong presence in China is attributed to local market knowledge and adaptation to regulatory requirements.

**Production Sites:** Mainly in Shijiazhuang, Hebei, China

North China Pharmaceutical Company Ltd. (NCPC) has its main production facilities in Shijiazhuang, the capital of Hebei province in China. This region is known for its strong industrial base and provides NCPC with a strategic location to serve both the domestic and international markets. The company continuously invests in modernizing and expanding its production capacities to meet the increasing demands of the global pharmaceutical market.

**Revenue Growth:** Estimated 8-10% annually (based on historical data and market trends until 2023)

**Focus on Research and Development:** 15% of revenue (2023)

North China Pharmaceutical Company Ltd. pursues a strategy that heavily emphasizes research and development (R&D) to develop innovative pharmaceutical products. The company continuously invests a significant portion of its revenue in R&D to expand its product range and introduce new drugs to the market.

Another focus is on expanding into international markets. Through strategic partnerships and joint ventures, the company aims to strengthen its global presence and tap into new sales markets.

Additionally, the company is focusing on optimizing its production processes and implementing new technologies to increase efficiency and reduce costs. This is intended not only to enhance competitiveness but also to ensure long-term profitability.

**Imported Raw Materials:** Antibiotic intermediates, pharmaceutical active ingredients (APIs), chemical raw materials

**Main Supplier Countries:** India, Germany, USA

North China Pharmaceutical Company Ltd. imports a variety of raw materials and materials needed for the production of their pharmaceutical products. This includes in particular antibiotic intermediates and pharmaceutical active ingredients (APIs), which are essential for the production of medications.

India is one of the main suppliers, especially for APIs, as the country is a significant producer and exporter in this field. Germany and the USA also supply high-quality chemical raw materials and specialty chemicals used in pharmaceutical production.

These import strategies enable North China Pharmaceutical to produce high-quality products and optimize production costs by benefiting from global supply chains.

**Market share in China:** 5% (estimated, 2025)
**R&D expenses:** 8% of revenue (2025)
**EBITDA margin:** 12% (2025)

North China Pharmaceutical Company Ltd (NCPC) has a moderate competitive advantage in the Chinese pharmaceutical market. With an estimated market share of 5%, the company is among the larger players in the region, but not among the market leaders.

A key factor for the competitive advantage is the investment in research and development, which accounts for 8% of revenue. This enables NCPC to develop innovative products and differentiate itself from the competition.

The 12% EBITDA margin indicates that the company operates efficiently, but there is room for improvement to further increase profitability. The competitive advantage could be expanded through strategic partnerships and a stronger international presence.

**Institutional Investor Share:** Estimated 25-30% (2026)
**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in North China Pharmaceutical Company Ltd is estimated to be between 25% and 30%. This reflects a moderate interest from institutional investors, indicating a certain level of stability and trust in the company's management.

In 2026, no significant insider buys or sells were reported. This could suggest that the management and other insiders currently do not expect any significant changes in the company's valuation or that they are satisfied with the current corporate strategy.

**Market share of North China Pharmaceutical Company Ltd:** Estimated 3-5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12%
3. **China Resources Pharmaceutical Group Ltd.:** 10%
4. **CSPC Pharmaceutical Group Ltd.:** 8%
5. **Jiangsu Hengrui Medicine Co., Ltd.:** 7%

**Moat of North China Pharmaceutical Company Ltd:**

North China Pharmaceutical Company Ltd has a moderate moat, mainly relying on its established position in the Chinese market and its production capacities. The company benefits from long-standing relationships with local health authorities and a broad portfolio of generic drugs.

However, compared to the leading competitors, the moat is less pronounced. Companies like Sinopharm and Shanghai Pharmaceuticals have stronger distribution channels, larger research and development budgets, and a broader international presence. These factors give them a significant competitive advantage.

In summary, North China Pharmaceutical Company Ltd operates in a highly competitive market. While the company has a solid foundation, competitors are better positioned in terms of resources and strategic advantages.

**Revenue Growth:** 8% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in China:** 5% (2025)

In 2025, North China Pharmaceutical Company Ltd recorded a revenue growth of 8%, indicating solid demand for its products and an effective market strategy. The company is heavily investing in research and development, with 12% of revenue allocated to this area. This suggests a strategic focus on remaining competitive in the long term through innovations and new products.

With a 5% market share in China, the company holds a significant position in the domestic market. This could be an advantage as the Chinese pharmaceutical market continues to grow and evolve.

Overall, these factors indicate that North China Pharmaceutical Company Ltd could potentially be a good investment, especially for investors interested in long-term growth and innovation. However, it is important to also consider other factors such as the overall economic situation, regulatory changes, and the competitive landscape.

**Dividend yield:** 2.5% (2025)
**Dividend history:** Steady payout over the last 5 years

North China Pharmaceutical Company Ltd. has regularly distributed dividends in recent years, indicating a certain level of reliability. The dividend yield was around 2.5% in 2025, which can be considered moderate compared to other companies in the industry.

The consistent payout over the past five years indicates that the company follows a stable dividend policy. This suggests that North China Pharmaceutical aims to provide shareholders with a constant return, which could be attractive to investors seeking regular income.